关于公司股票被实施其他风险警示相关事项的进展公告 江苏天瑞仪器股份有限公司因收到中国证监会出具的《行政处罚事先告知书》，触及《深圳证券交易所 创业板股票上市规则》第9.4条第（七）项规定，公司股票自2024年12月10日起被实施其他风险警示。 公司已于2025年3月18日收到《行政处罚决定书》，认定情况与事先告知书一致。公司已对2021年年报 进行会计差错更正并追溯调整，相关整改已完成。公司将按规定申请撤销风险警示。 截至2026年2月2日收盘，ST天瑞(300165)报收于4.94元，下跌1.4%，换手率1.38%，成交量5.81万手，成 交额2900.5万元。 当日关注点 交易信息汇总 资金流向 2月2日主力资金净流入18.18万元；游资资金净流出29.98万元；散户资金净流入11.8万元。 公司公告汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：2月2日主力资金净流入18.18万元，散户资金同步净流入，显示市场多方力量 略有占优。 来自公司公告汇总：ST天瑞已收到证监会正式处罚决定书，并完成2021年年 ...

证券代码：300165 证券简称：ST天瑞 公告编号：2026-004 江苏天瑞仪器股份有限公司 一、实施其他风险警示的原因 公司于2024年12月6日收到中国证监会出具的《行政处罚事先告知书》，根据 《行政处罚事先告知书》认定的情况，公司涉及的违法违规行为触及《深圳证券 交易所创业板股票上市规则》第9.4条第（七）项规定的被实施其他风险警示情形， 公司股票于2024年12月10日起被实施其他风险警示，具体内容详见公司在巨潮资 讯网上披露的《关于公司股票交易被实施其他风险警示暨股票停复牌的提示性公 告》（公告编号：2024-074）。 二、采取的措施及进展情况 1、针对《行政处罚决定书》所涉事项，公司于2024年4月24日召开了第六 届董事会第七次会议和第六届监事会第五次会议，审议通过了《关于前期会计 差错更正及追溯调整的议案》，对2021年年报进行了会计差错更正及追溯调整， 并于2024年4月26日披露了《关于公司前期会计差错更正及追溯调整的公告》 （公告编号：2024-015）等相关文件。目前，公司不存在尚未整改完毕的事项。 关于公司股票被实施其他风险警示相关事项的进展公告 本公司及董事会全体成员保证信息 ...

Core Viewpoint - ST Tianrui (300165.SZ) expects a net profit attributable to shareholders of the listed company to be between -240 million and -170 million yuan for 2025, with a net profit after deducting non-recurring gains and losses estimated at -246.51 million to -176.51 million yuan [1] Financial Performance - The company anticipates a significant net loss for 2025, indicating ongoing financial challenges [1] - The projected net loss reflects a deterioration in market conditions affecting the company's operations [1] Project Status - The company's subsidiary, Qingshui Jingsheng Living Waste Resource Utilization Co., Ltd., has halted its PPP project due to changes in market conditions and plans to pursue external transfer of the project [1] - In accordance with the relevant provisions of the Accounting Standards for Enterprises No. 8 on asset impairment, the company plans to make an asset impairment provision of 85 million to 100 million yuan for the related contract assets of the project [1]

证券代码：300165 证券简称：ST天瑞 公告编号：2026-003 江苏天瑞仪器股份有限公司 关于控股股东收到仲裁裁决书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，江苏天瑞仪器股份有限公司（以下简称"公司"或"天瑞仪器"）收 到公司控股股东刘召贵先生提交的上海国际经济贸易仲裁委员会（上海国际仲裁 中心）出具的《裁决书》（上国仲（2025）第 1729 号），上海国际经济贸易仲 裁委员会（上海国际仲裁中心）就刘召贵先生与广州立多虚拟现实科技合伙企业 (有限合伙)(以下简称"立多虚拟")之间股份转让协议纠纷事项做出终局裁决， 现将相关情况公告如下： 一、情况概述 2023 年 5 月 12 日，刘召贵先生与立多虚拟签订《刘召贵与广州立多虚拟现 实科技合伙企业(有限合伙)关于江苏天瑞仪器股份有限公司之股份转让协议》， 约定将其名下 5.01%的天瑞仪器股份以 4.7 元/股的价格转让给立多虚拟，合同总 价款为 116,678,143.90 元。 2023 年 5 月 19 日，立多虚拟按照合同约定向刘召贵先生支付了第一笔转让 款，即合同总价款的 ...

一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 证券代码：300165 证券简称：ST 天瑞 公告编号：2026-002 江苏天瑞仪器股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、报告期内，公司依据《企业会计准则第 1 号—存货》的规定，结合公司的会 计政策，并遵循谨慎性原则，预计计提存货跌价准备 3,500 万元至 4,000 万元。 3、报告期内，结合公司实际情况，根据《企业会计准则第 8 号—资产减值》及相 关会计政策规定，基于对子公司上海贝西生物科技有限公司、江苏国测检测技术有限 公司主营业务构成及未来预期的判断，从审慎性原则出发，经公司初步测算，预计计 提这两家子公司商誉减值约 3,500 万元至 4,180 万元。 截至目前，相关资产减值测试尚在进行中，最终减值准备计提的金额将由公司聘 请的专业评估机构及年审会计机构进行评估和审计后确定。 四、其他相关说明 （1）以区间数进行业绩预告的 二、与会计师事务所沟通情 ...

证券代码：300165 证券简称：ST天瑞 公告编号：2026-001 江苏天瑞仪器股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、实施其他风险警示的原因 公司于2024年12月6日收到中国证监会出具的《行政处罚事先告知书》，根据 《行政处罚事先告知书》认定的情况，公司涉及的违法违规行为触及《深圳证券 交易所创业板股票上市规则》第9.4条第（七）项规定的被实施其他风险警示情形， 公司股票于2024年12月10日起被实施其他风险警示，具体内容详见公司在巨潮资 讯网上披露的《关于公司股票交易被实施其他风险警示暨股票停复牌的提示性公 告》（公告编号：2024-074）。 二、采取的措施及进展情况 1、针对《行政处罚决定书》所涉事项，公司于2024年4月24日召开了第六 届董事会第七次会议和第六届监事会第五次会议，审议通过了《关于前期会计 差错更正及追溯调整的议案》，对2021年年报进行了会计差错更正及追溯调整， 并于2024年4月26日披露了《关于公司前期会计差错更正及追溯调整的公告》 ...

Core Viewpoint - ST Tianrui has resumed trading after terminating the planned change of control, with the stock closing at 4.60 yuan, reflecting a decline of 0.86% and a total market capitalization of 2.279 billion yuan [1]. Group 1 - The company announced the termination of the planned change of control due to a lack of consensus between the controlling shareholder and the counterparties involved [1]. - The decision to terminate the control change was made in a cautious manner, ensuring that it would not have a significant adverse impact on the company's operational performance and financial status [1]. - The company’s operations remain normal despite the termination of the control change plan [1]. Group 2 - The company applied to the Shenzhen Stock Exchange for the resumption of trading, which took effect on December 8, 2025 [2].

Core Viewpoint - The establishment of the Analysis Instrument Professional Committee under the China Nuclear Instrument Association marks a significant step towards integrating industry resources, promoting collaborative innovation, and strengthening standard leadership in the nuclear instrument sector [2][8][25]. Group 1: Event Overview - The founding conference of the Analysis Instrument Professional Committee took place on December 5, 2025, in Beijing, attended by industry professionals and experts [2][5]. - The meeting was hosted by Ma Jing, Chief Expert of China National Nuclear Corporation, with notable attendees including leaders from the National Defense Science and Technology Industry Bureau and the China Nuclear Instrument Association [2][8]. Group 2: Leadership and Structure - The conference included the election of the first council members, with Hou Liudong elected as the chairman and several vice-chairmen and directors appointed [13]. - The establishment of the committee was officially recognized with a plaque presentation by Xu Pengfei, representing the China Nuclear Instrument Association [13][25]. Group 3: Strategic Importance - The committee aims to address the increasing demands for precision, reliability, intelligence, and localization in analysis instruments due to the deepening application of nuclear technology across various sectors [25]. - There is a pressing need for breakthroughs in key technologies, construction of standard systems, and deep integration of production, learning, research, and application to enhance the overall capabilities of the industry and ensure the security of the industrial chain [25]. Group 4: Academic Contributions - The conference featured high-level reports from renowned experts in the field, covering topics such as single-cell immune mass spectrometry and key technologies for digitalization of material properties [20][21]. - These discussions provided significant academic insights and shared cutting-edge technologies relevant to the analysis instrument sector [20].

Group 1 - Century Huatong plans to change the use of 1.28 million repurchased shares from equity incentive plans to cancellation, reducing total share capital from 7.428 billion to 7.427 billion shares [2] - Wuliangye adjusts its 2025 investment plan, increasing the number of projects from 19 to 22 and changing the investment amount from 2.586 billion to 2.207 billion yuan [3] - Qingyue Technology is under investigation for suspected financial data fraud, with the possibility of forced delisting if found guilty [4] Group 2 - Kang Enbei's chairman and legal representative resigns due to work adjustments, along with another board member [5] - Tianshan Co. expects a tax payment of approximately 61.86 million yuan to impact its 2025 net profit [6] - Muyuan Foods reports a 20.43% year-on-year decline in November sales revenue from live pigs, totaling 9.39 billion yuan [7] Group 3 - GAC Group's November automobile sales decreased by 9.72% year-on-year, with total sales of 1.797 million vehicles [8] - Western Pastoral's fresh milk production in November increased by 6.3% month-on-month but decreased by 6.47% year-on-year [9] - Gemdale Group's November contracted area fell by 58.50% year-on-year, with a total contracted amount of 1.52 billion yuan [10] Group 4 - Zhenghong Technology reports November sales revenue of 4.5196 million yuan from live pigs, with a year-on-year decline of 21.83% [11] - Wens Foodstuff's November chicken sales reached 118 million birds, generating 3.324 billion yuan in revenue [12] - Meilixin's controlling shareholder plans to increase holdings by no less than 50 million yuan [13] Group 5 - Hongcheng Environment's subsidiary wins an 853 million yuan sewage treatment project [14] - Dongzhu Ecology wins a 397 million yuan environmental project [15] - Xindian Software secures a 54 million yuan project for digital community construction [16] Group 6 - China Chemical announces that its nylon new material project has reached full production [17] - Jiaojian Co. is in discussions regarding overdue payments related to financial products, clarifying that it bears no responsibility for these products [18] - Micron Biotech's product is included in the 2025 National Medical Insurance Directory [19] Group 7 - Yitian Intelligent plans to sell 600 smart computing machines for a total of 1.56 billion yuan [20] - First Venture's subsidiary receives an administrative penalty notice from Jiangsu Securities Regulatory Bureau [21] - China Insurance's vice president is under investigation for serious violations [22] Group 8 - Zhixiang Jintai's monoclonal antibody injection is included in the 2025 National Medical Insurance Directory [23] - Haichuang Pharmaceutical's drug is also included in the National Medical Insurance Directory [24] - Yuanli Co. plans to acquire 49% of Clarimex for 25.56 million USD [25] Group 9 - Betta Pharmaceuticals' products are included in the National Medical Insurance Directory [26] - Tianci Materials' controlling shareholder commits to not reducing holdings for six months [27] - Guanglian Aviation's actual controller has had a detention measure lifted [28] Group 10 - Annie Co. announces a share transfer agreement that will make Shengshi Tianan the controlling shareholder [29] - Double Star New Materials notes uncertainty regarding the sustainability of long-term price increases [30] - ST Tianrui terminates plans for a change in control and resumes trading [31] Group 11 - Guao Technology is planning a change in control, leading to a temporary suspension of its stock [32] - Guangqi Technology's subsidiary signs contracts worth 696 million yuan for the production of metamaterials [33] - Shuoshi Biotech's monkeypox virus detection kit is included in the WHO emergency use list [34]

Core Viewpoint - Jiangsu Tianrui Instrument Co., Ltd. has terminated the planning of a change in company control, which will not adversely affect its operations or future development strategy [2][3]. Group 1: Suspension of Trading - The company's stock (ST Tianrui, stock code: 300165) was suspended from trading starting December 1, 2025, due to the potential change in control involving the controlling shareholder and actual controller Liu Zhaogui [2]. - The suspension was implemented to ensure fair information disclosure and prevent abnormal fluctuations in the stock price during the planning phase of the control change [2]. Group 2: Termination of Control Change Planning - The termination of the control change planning was due to the lack of consensus on significant matters between the controlling shareholder and the transaction counterpart [3]. - The company confirmed that its operational status remains normal and that the termination will not have a significant adverse impact on its financial performance [3]. Group 3: Resumption of Trading - The company's stock is set to resume trading on December 8, 2025, following the termination of the control change planning [4]. - The company has expressed apologies for any inconvenience caused to investors due to the termination of the control change planning [4].